Kim DY, Lee HW, Kang W, et al. - In this study, whether the metabolic activity assessed by ¹⁸F‐fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) had any predictive value was explored in patients with hepatocellular carcinoma (HCC) undergoing Yttrium‐90 (Y‐90) transarterial radioembolization (TARE). A total of 40 patients with HCC were treated with Y‐90 TARE between 2009 and 2013. ¹⁸F‐FDG PET/CT was conducted before each treatment. For each patient, researchers assessed maximum standardized uptake value (SUVmax) and tumor‐to‐non‐tumorous liver uptake ratio (TLR; tumor SUVmax/non‐tumorous liver mean SUV). The results of this study illustrated that TLR‐based stratification is a simple method, but it may not be useful in treatment planning for HCC patients undergoing Y‐90 TARE. Future trials with a large number of patients are required. Rates of disease control, progression‐free survival, or overall survival were not impacted by low and high TLR (relative to the median value of 2.1). In patients with HCC undergoing Y‐90 TARE, no predictive factors could be identified for disease progression or death.